Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice
- PMID: 9272693
- DOI: 10.1016/s0304-3940(97)00515-6
Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice
Abstract
We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.
Similar articles
-
Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain.Brain Res. 1996 Sep 9;733(1):101-4. doi: 10.1016/0006-8993(96)00686-5. Brain Res. 1996. PMID: 8891252
-
Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.Exp Neurol. 1997 Aug;146(2):526-35. doi: 10.1006/exnr.1997.6575. Exp Neurol. 1997. PMID: 9270064
-
Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.J Pharm Pharmacol. 1999 Dec;51(12):1405-8. doi: 10.1211/0022357991777038. J Pharm Pharmacol. 1999. PMID: 10678495
-
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.Neuropharmacology. 2014 Jan;76 Pt A:156-68. doi: 10.1016/j.neuropharm.2013.07.016. Epub 2013 Aug 20. Neuropharmacology. 2014. PMID: 23973568
-
Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications.J Am Coll Surg. 2002 Nov;195(5):694-712. doi: 10.1016/s1072-7515(02)01491-6. J Am Coll Surg. 2002. PMID: 12437261 Review. No abstract available.
Cited by
-
Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients.Mitochondrion. 2010 Mar;10(2):94-101. doi: 10.1016/j.mito.2009.10.001. Epub 2009 Oct 31. Mitochondrion. 2010. PMID: 19836469 Free PMC article.
-
Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia.Neurochem Res. 1999 Jan;24(1):9-13. doi: 10.1023/a:1020915727119. Neurochem Res. 1999. PMID: 9973231
-
The future use of complement inhibitors for the treatment of neurological diseases.Drugs. 1998 Jun;55(6):739-46. doi: 10.2165/00003495-199855060-00001. Drugs. 1998. PMID: 9617589 Review.
-
Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.Acta Neuropathol Commun. 2015 Dec 14;3:84. doi: 10.1186/s40478-015-0263-6. Acta Neuropathol Commun. 2015. PMID: 26666562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous